JosephIClarkMDFACP

Genitourinary Oncology, Head & Neck Cancer, Melanoma

Division Director Hematology/Oncology. Professor of Medicine, Loyola University-Stritch School of Medicine. Loyola University Health System

Join to view full profile

Dr. Clark is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Clark's full profile

Already have an account?

Office
Cardinal Bernardin Cancer Center, Room 263
2160 S. First Avenue
Maywood, IL 60153
Phone+1 708-327-3236

Fax+1 708-327-3319
Is this information wrong?

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
Loyola University Medical CenterResidency, Internal Medicine, 1989 - 1992
Loyola University Chicago Stritch School of MedicineClass of 1989

Certifications & Licensure

IL State Medical License 1989 - 2026
PA State Medical License 1992 - 1996
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018-2021
West Suburban Living Magazine Castle Connolly, 2014, 2017
Top Doctor in Medical Oncology U.S. News and World Report, 2011
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Start of enrollment: 1997 Jun 01
Completed
Phase 3
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2005 Jun 01
Completed
Phase 2
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients Start of enrollment: 2012 Jul 01
Active, not recruiting
Phase 1
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Nov 26
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Implementing a cognitive behavioral intervention for patients with head and neck cancer.
Sarah Thilges, Patricia Mumby, James Sinacore, Joseph Clark, Cheryl Czerlanis> ;Supportive Care in Cancer. 2023 Jul 19
21 citations
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective.
Asser Abou Elkassem, Simon S. Lo, Andrew J. Gunn, Brian Shuch, Molly E. DeWitt-Foy, Robert Abouassaly, Sandeep Vaidya, Joseph I. Clark, Alexander V. Louie, Shankar Siv...> ;Radiographics. 2021 Jul 16
6 citations
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
, , , , , , , , , , , , , , , , > ;Molecular Therapy Oncolytics. 2021 Mar 26
1 citations
Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?
Hiten D. Patel, Joseph I. Clark, Robert C. Flanigan> ;The Journal of Urology. 2021 Feb 9
11 citations
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Joseph I. Clark, Brendan Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin, Ajjai Alva, Theodore F. Logan, Ralph J. Hauke, Gerald P Miletello, Ulka N. Vaishampay...> ;Journal of Investigative Medicine. 2021 Feb 4
65 citations
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. M...> ;Nature Medicine. 2020 Oct 5
11 citations
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.
Ann W. Silk, Howard L. Kaufman, Brendan D. Curti, Janice M. Mehnert, Kim Margolin, David F. McDermott, Joseph I. Clark, Jenna H. Newman, Praveen K. Bommareddy, Lisa K....> ;Frontiers in Oncology. 2020 Jan 10
4 citations
Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.
Daniel R. Principe, Joseph I. Clark, Bahman Emami, Stanley Borowicz> ;BMJ Case Reports. 2019 Aug 1
3 citations
Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Petar Bajic, Robert C. Flanigan, Cara Joyce, Joseph I. Clark> ;The Journal of Urology. 2019 Mar 1
33 citations
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM re...
Mayer Fishman, Janice P. Dutcher, Joseph I. Clark, Ajjai Alva, Gerald P Miletello, Brendan Curti, Neeraj Agarwal, Ralph J. Hauke, Kathleen M. Mahoney, Helen Moon, J. T...> ;Journal for Immunotherapy of Cancer. 2019 Mar 27
89 citations
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna Pradyuman Patel, Shernan G. Holtan, Gerald P Miletello, Mayer Fishman, Rene Gon...> ;Journal for Immunotherapy of Cancer. 2019 Feb 18
15 citations
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan D. Curti, Sanjiv S. Agarwala, Bret Taback, Lee ...> ;Journal for Immunotherapy of Cancer. 2018 Jul 27
1 citations
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
Joseph I. Clark, Shams Bufalino, Shruti Singh, Ewa Borys> ;Journal for Immunotherapy of Cancer. 2018 Jun 14
51 citations
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie A. Fecher, Thomas F. Gajewski, Brian R. Gastman, D...> ;Journal for Immunotherapy of Cancer. 2018 May 30
13 citations
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, Kelli A Hutchens, Constantine Godellas, Ann Lau Clark, Elizabeth Motunrayo Kolawole, Lance M Hellman, Nishant K Sin...> ;Cancer Immunology, Immunotherapy. 2018 Feb 1
3 citations
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells (Cancer Immun...
Tamson V. Moore, Courtney Regan Wagner, Gina Scurti, Kelli A. Hutchens, Constantine Godellas, Ann Lau Clark, Elizabeth Motunrayo Kolawole, Lance M. Hellman, Nishant K....> ;Cancer Immunology, Immunotherapy. 2018 Feb 1
24 citations
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
Brendan D. Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy C. ...> ;Journal for Immunotherapy of Cancer. 2017 Dec 19
104 citations
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
Michael B. Atkins, Joseph I. Clark, David I. Quinn> ;Annals of Oncology. 2017 Jul 1
25 citations
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
29 citations
Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.
Jared Klarquist, Kristen Tobin, Peyman Farhangi Oskuei, Steven W. Henning, Manuel F. Fernandez, Emilia R. Dellacecca, Flor Navarro, Jonathan M. Eby, Shilpak Chatterjee...> ;Cancer Research. 2016 Nov 1
67 citations
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A. Daniels, Michael K.K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald P Miletello, Th...> ;Cancer Immunology, Immunotherapy. 2016 Oct 6
30 citations
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica C. Perritt, Janice P. Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curt...> ;Journal for Immunotherapy of Cancer. 2016 Sep 20
479 citations
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott, Matteo S. Carlino, Nikhil I. Khushalani, Fei Ye, Alexander Guminski, Igor Puzanov, Donald P. Lawrence, Elizabeth ...> ;JAMA Oncology. 2016 Feb 1
24 citations
Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence ☆
G.J. Petruzzelli, J.B. Howell, A. Pederson, Thomas C. Origitano, Richard W. Byrne, Lorenzo F. Munoz, Bahman Emami, Joseph I. Clark> ;American Journal of Otolaryngology. 2015 Jul 1
14 citations
Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy.
James J. Jaber, Lauren L. Murrill, Joseph I. Clark, Jonas T. Johnson, Paul J. Feustel, Vikas Mehta> ;Otolaryngology--Head and Neck Surgery. 2015 Apr 27
Join now to see all